Key Drivers
- Strong cash cushion
- No revenue
- High cash burn
AIAI Summary
PHVS should now be viewed as a late-stage, catalyst-driven regulatory asset rather than an early biotech, but with the stock already pricing in substantial success and a long wait to the 2027 PDUFA, the main actionable takeaway is that upside likely depends on clean clinical/regulatory execution and a decisive break above resistance near $36.5.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash cushion
- •No revenue
- •High cash burn
PHVS has a very strong cash position and minimal debt, but its lack of revenue, persistent losses, and substantial cash burn mean the investment case depends more on liquidity than on operating performance.
Price Behavior
Key Price Behavior Insights:
- •Range-bound trade
- •Holding support
- •Stalled resistance
PHVS has been range-bound over the last month with a modestly constructive tone, holding above mid-34 support but still facing repeated rejection near $36.0-$36.5.
Sharp drop on 2026-08-13 after the recent peak suggests active selling pressure
Sentiment & News
Key News Insights:
- •NDA Acceptance
- •Phase 3 Catalysts
- •Mixed Sentiment
PHVS advanced its hereditary/acquired angioedema franchise with supportive science, FDA acceptance of the deucrictibant IR NDA, and near-term Phase 3 catalysts, while insider selling and mixed analyst sentiment kept the stock view balanced.
The news is broadly supportive for PHVS as it de-risks the program and builds momentum, but the shares will likely stay data-driven until upcoming trial and regulatory milestones are cleared
Similar Companies in Healthcare
Other companies in the same sector with AI ratings